It might not straight away give out that impression, but in all honesty, everything around us is a result of many different takes coming together to produce a version that fits best into the fabric of our lives. This idea, as you can imagine, is born out of human ability to communicate and collaborate. We, as individuals, are always in the known about our perception being somewhat lopsided; hence we foster partnerships with other human beings to balance out our attempts at improving our lives. Our tendency to do so has paid enormous dividends over the years; however, it reached the point of crescendo when we worked together to bring technology into existence. Apart from all the creation’s direct benefits, we also had more productive opportunities to collaborate in future. A scenario of such sort brought every imaginable milestone within our reach, and we have so far made the most of it. The ripple effects of this transition have been felt all over the place, but one area where the progression seemed slightly more important is healthcare. After scaling up the treatments, the sector is now actively looking to allow people the power to control their health, instead of it being the other way around, and some recent events do everything to signify that we are closer to the said reality than we think.
Harvard University’s spinout, GRO Biosciences has just received a boost in its pursuit of developing protein therapies that are safer and more effective, as the entity’s $25 million funding became official on Wednesday. GRObio has long talked about the limitations of current protein therapies, which are, more often than not, restricted to 20 standard amino acids. You see, amino acids are one of the cornerstones for every protein out there, so utilizing them in a limited capacity significantly hinders our real potential in this regard. GRObio’s plans of expanding the amino acids alphabet aren’t just projected to help protein therapies in absolute terms, but they are also expected to elevate our overall well-being.
Backed with some fresh funding from Leaps by Bayer and Redmile Group, GRObio would be now looking to execute its vision of recoding E.Coli bacteria. E.Coli is widely-used across the industry mainly due to its economic feasibility. Nevertheless, by recoding the bacteria, the Harvard subsidiary is going to barge ahead and bring NSAAs into the picture. The motivation behind it is the possibility of creating customized proteins that can mould themselves as per the needs of a biologic drug and the purpose they are being used to fulfill. As of now, GRObio has refrained from revealing what area of healthcare they specifically have in focus, but reports do claim that the new therapies will have something for autoimmune and metabolic disorders. As far as trials are concerned, the subsidiary is tentatively looking at 2024 to be a realistic target.
